Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Postmenopausal osteoporosis is the most common form of osteoporosis. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture.

The Post Menopausal Osteoporosis pipeline drugs market research report outlays comprehensive information on the Post Menopausal Osteoporosis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Post Menopausal Osteoporosis targeted therapeutics development with respective active and dormant or discontinued projects.

Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Post Menopausal Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Sclerostin, Activin Receptor Type 2A, Adrenomedullin, Calcitonin Receptor, Dedicator Of Cytokinesis Protein 5, Estrogen Receptor, and Iron. Tumor Necrosis Factor Ligand Superfamily Member 11 accounted for the largest target in the Post Menopausal Osteoporosis pipeline drugs market.

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Targets

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample

Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Post Menopausal Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Sclerostin Inhibitor, Calcitonin Receptor Agonist, Dedicator Of Cytokinesis Protein 5 Inhibitor, Estrogen Receptor Agonist, Iron Chelator, Parathyroid Hormone Activator, Tumor Necrosis Factor Receptor Superfamily Member 11A Inhibitor, and Vitamin D Receptor Agonist. Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor has the maximum number of products in the Post Menopausal Osteoporosis pipeline drugs market.

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Mechanisms of Action

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample

Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Post Menopausal Osteoporosis pipeline drugs market are subcutaneous, oral, parenteral, transdermal, and intravenous. Subcutaneous has the majority number of products in the Post Menopausal Osteoporosis pipeline drugs market.

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Routes of Administration

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample

Post Menopausal Osteoporosis Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the Post Menopausal Osteoporosis pipeline drugs market are Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Small Molecule, Synthetic Peptide, Biologic, and Gene Therapy.

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Molecule Type

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Post Menopausal Osteoporosis pipeline drugs market are Biocon Ltd, Eden Biologics Inc, Enteris BioPharma Inc, Ipsen SA, Luye Pharma Group Ltd, Shanghai Henlius Biotech Inc, Uni-Bio Science Group Ltd, Ablynx NV, Addpharma Inc, and Airsea (Taizhou) Pharmaceutical Ltd. Biocon Ltd accounted for the largest Post Menopausal Osteoporosis pipeline drugs market share in 2022.

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Leading Companies

Post Menopausal Osteoporosis Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the Post Menopausal Osteoporosis pipeline drugs market, download a free report sample

Post Menopausal Osteoporosis Pipeline Drugs Market Report Overview

Key Targets Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Sclerostin, Activin Receptor Type 2A, Adrenomedullin, Calcitonin Receptor, Dedicator Of Cytokinesis Protein 5, Estrogen Receptor, and Iron
Key Mechanisms of Action Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Sclerostin Inhibitor, Calcitonin Receptor Agonist, Dedicator Of Cytokinesis Protein 5 Inhibitor, Estrogen Receptor Agonist, Iron Chelator, Parathyroid Hormone Activator, Tumor Necrosis Factor Receptor Superfamily Member 11A Inhibitor, and Vitamin D Receptor Agonist
Key Routes of Administration Subcutaneous, Oral, Parenteral, Transdermal, and Intravenous
Key Molecule Types Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Small Molecule, Synthetic Peptide, Biologic, and Gene Therapy
Key Companies Biocon Ltd, Eden Biologics Inc, Enteris BioPharma Inc, Ipsen SA, Luye Pharma Group Ltd, Shanghai Henlius Biotech Inc, Uni-Bio Science Group Ltd, Ablynx NV, Addpharma Inc, and Airsea (Taizhou) Pharmaceutical Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Ablynx NV
Addpharma Inc
Airsea (Taizhou) Pharmaceutical Ltd
AlphaMab Co Ltd
Alvotech SA
Amgen Inc
Aryogen Pharmed Co
Beijing Kangleweishi Biotechnology Co Ltd
Beijing Northland Biotech Co Ltd
Biocon Ltd
Celltrion Inc
Clayton Biotechnologies Inc
Clonz Biotech Pvt Ltd
CSPC Pharmaceutical Group Ltd
Eden Biologics Inc
Eli Lilly and Co
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Epygen Biotech Pvt Ltd
Fresenius Kabi SwissBioSim GmbH
Gedeon Richter Plc
Genor BioPharma Co Ltd
Hualan Biological Engineering Inc
Intas Pharmaceuticals Ltd
Ipsen SA
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabxience Holding SL
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
Paras Biopharmaceuticals Finland Oy
Qilu Pharmaceutical Co Ltd
Reliance Life Sciences Pvt Ltd
Samsung Bioepis Co Ltd
Sandoz International GmbH
Shandong New Time Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Mab Venture Biopharm Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Uni-Bio Science Group Ltd
Wuxi Hebang Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post Menopausal Osteoporosis – Overview

Post Menopausal Osteoporosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Post Menopausal Osteoporosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post Menopausal Osteoporosis – Companies Involved in Therapeutics Development

Post Menopausal Osteoporosis – Drug Profiles

Post Menopausal Osteoporosis – Dormant Projects

Post Menopausal Osteoporosis – Discontinued Products

Post Menopausal Osteoporosis – Product Development Milestones

Featured News & Press Releases

Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT

Jun 17, 2022: Voluntary announcement – First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China

Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS

Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System

Dec 23, 2021: Radius announces update on TYMLOS (abaloparatide) label

Dec 08, 2021: Radius announces results from the wearABLe trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis

Oct 06, 2021: Entera Bio presents positive phase 2 6-month bone mineral density data for oral PTH formulation at Late Breaker ASBMR Conference Session

Sep 22, 2021: Radius Health announces TYMLOS label and business update

Sep 01, 2021: Entera Bio selected for late breaking oral presentation of phase 2 6-month osteoporosis data at ASBMR 2021 Annual Meeting

Jan 25, 2021: Luye Pharma LY06006 completed the last dosing for all subjects in phase III Clinical in China

Dec 14, 2020: Samsung Bioepis initiates phase 3 clinical trial for SB16, proposed biosimilar to Prolia (Denosumab)

Oct 23, 2020: Boan Biotech receives EU clinical trials application approval for Denosumab injection

Sep 09, 2020: Radius Health announces scientific presentations on abaloparatide at ASBMR 2020 Annual Meeting

Sep 08, 2020: Radius Health: Enrollment completed for Phase 3 wearABLe trial

Aug 20, 2020: Entera Bio announces interim data from phase 2 clinical trial of EB613 in osteoporosis and second quarter 2020 financial results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Post Menopausal Osteoporosis – Dormant Projects, 2022

Post Menopausal Osteoporosis – Dormant Projects, 2022 (Contd..1)

Post Menopausal Osteoporosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Post Menopausal Osteoporosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.